Fast Market Research

Now Available: Metastatic Melanoma - Pipeline Review, H1 2014

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research


Boston, MA -- (SBWIRE) -- 05/20/2014 -- Summary

Global Markets Direct's, 'Metastatic Melanoma - Pipeline Review, H1 2014', provides an overview of the Metastatic Melanoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

View Full Report Details and Table of Contents

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Melanoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects

Companies Mentioned in this Report: Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Vical Incorporated, Amgen Inc., Sanofi, AstraZeneca PLC, GlaxoSmithKline plc, Genentech, Inc., MedImmune, LLC, Plexxikon Inc., Delcath Systems, Inc., Millennium Pharmaceuticals, Inc., Novartis AG, Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Celgene Corporation, Bayer AG, Incyte Corporation, Luitpold Pharmaceuticals, Inc., Merck KGaA, Celldex Therapeutics, Inc., Momenta Pharmaceuticals, Inc., AVAX Technologies, Inc., Oncolytics Biotech Inc., Antisoma plc, Progen Pharmaceuticals Limited, HanAll Biopharma Co., Ltd., Provectus Biopharmaceuticals, Inc., BioAlliance Pharma SA, Scancell Holdings Plc, Morphotek, Inc., DNA Therapeutics S.A., Philogen S.p.A., siRNAsense AS, Altor BioScience Corporation, Deciphera Pharmaceuticals, LLC, Affichem, Immutep S.A., Polyphor Ltd., Omeros Corporation, ImmuRx, Inc., AB Science, CureTech Ltd., WntResearch AB, Life Science Pharmaceuticals, Incorporated, Cancer Therapeutics CRC Pty Ltd, Cytavis Biopharma GmbH, n.v. BRUCELLS s.a., California Stem Cell, Inc., Lipotek Pty Ltd., Immunophotonics Inc, OncoSec Medical Inc., Vaxeal Holding SA, Bioncotech Therapeutics S.L., AbbVie Inc., Agalimmune Ltd

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Metastatic Breast Cancer - Pipeline Review, H1 2014
- Metastatic Colorectal Cancer - Pipeline Review, H1 2014
- Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014
- Metastatic Pancreatic Cancer - Pipeline Review, H1 2014
- Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2014
- Metastatic Prostate Cancer - Pipeline Review, H1 2014
- Metastatic Ovarian Cancer - Pipeline Review, H1 2014
- Metastatic Liver Cancer - Pipeline Review, H1 2014
- Metastatic Uveal Melanoma Global Clinical Trials Review, H1, 2014
- Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014